Tiotropium: A bronchodilator for chronic obstructive pulmonary disease

Annals of Pharmacotherapy

Volumn 39, Issue 9, 2005, Pages 1467-1475

  Somand, Heather ^a   Remington, Tami L ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Chronic obstructive pulmonary disease; Tiotropium

Indexed keywords

BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FORMOTEROL; IPRATROPIUM BROMIDE; PLACEBO; SALBUTAMOL; SALMETEROL; STEROID; THEOPHYLLINE; TIOTROPIUM BROMIDE;

CHRONIC DRUG ADMINISTRATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONSTIPATION; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; DYSPNEA; FORCED EXPIRATORY VOLUME; GLAUCOMA; HEART ARRHYTHMIA; HUMAN; KIDNEY DYSFUNCTION; LUNG FUNCTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYMPTOMATOLOGY; TREATMENT OUTCOME; URINARY TRACT INFECTION; URINE RETENTION; VISUAL IMPAIRMENT;

ALBUTEROL; BRONCHODILATOR AGENTS; CHOLINERGIC ANTAGONISTS; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; EXERCISE; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; RESPIRATORY FUNCTION TESTS; SCOPOLAMINE DERIVATIVES;

EID: 23944515256     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E469     Document Type: Review

References (38)

1. Fabbri L, Barnes P, Buist S, Calverley P, Fukuchi Y, MacNee W, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2004 update, www.goldcopd.com/ (accessed 2005 Mar 15).
2. Kochanek KD, Murphy SL, Anderson RN, Scott C. Deaths: final data for 2002. National Vital Statistics Reports 2004;53(5):1-116.
3. American Thoracic Society, European Respiratory Society. Standards for the diagnosis and management of patients with COPD. www.thoracic. org/copd (accessed 2005 Mar 15).
4. Witek TJ Jr, Souhrada JF, Serby CW, Disse B. Tiotropium (BA 679): pharmacotherapy and early clinical observations. In: Spector SL, ed. Anticholinergic agents in the upper and lower airways. New York: Dekker, 1999:137-52.
5. Disse B, Reichl R, Speck G, Traunecker W, Ludwig Rominger KL, Hammer R. BA679 BR, a novel long-acting anticholinergic bronchodilator. Life Sci 1993;52:537-44.
6. Barnes PJ. Muscarinic receptor subtypes in airways. Life Sci 1993;52: 521-7.
7. Takahashi T, Belvisi MG, Patel H, Ward JK, Tadjkarimi S, Yacoub MH, et al. Effect of BA 679 BR, a novel long-acting anticholinergic agent, on cholinergic neurotransmission in guinea pig and human airways. Am J Respir Crit Care Med 1994;150:1640-50.
8. Casaburi R, Briggs D Jr, Donohue JF, Serby CW, Menjoge SS, Witek TJ Jr. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. Chest 2000;118:1294-302.
9. Vincken W, van Noord JA, Greefhorst APM, Bantje TA, Kesten S, Korducki L, et al. Improved health outcomes in patients with COPD during 1 year's treatment with tiotropium. Eur Respir J 2002; 19:209-16.
10. Cazzola M, Di Marco F, Santus P, Boveri B, Verga M, Matera M, et al. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther 2004;17:35-9.
11. van Noord JA, Bantje TA, Eland ME, Korducki L, Cornelissen PJG. A randomized controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. Thorax 2000;55: 289-94.
12. van Noord JA, Smeets JJ, Custers FLJ, Korducki L, Cornelissen PJG. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur Respir J 2002;19:639-44.
13. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 1991;144:1202-18.
14. Disse B, Speck G, Rominger KL, Witek TJ Jr, Hammer R. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 1999;64:457-64.
15. Witek TJ Jr. The fate of inhaled drugs: the pharmacokinetics and pharmacodynamics of drugs administered by aerosol. Respir Care 2000;45: 826-30.
16. Littner MR, Ilowite JS, Tashkin DP, Friedman M, Serby CW, Menjoge SS, et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1136-42.
17. Maesen FPV, Smeets JJ, Sledsens TJH, Wald FDM, Cornelissen PJG. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Eur Respir J 1995;8:1506-13.
18. Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217-24.
19. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003;58:399-404.
20. Celli B, ZuWallack RL, Wang S, Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003;124:1743-8.
21. Yusen R. What outcomes should be measured in patients with COPD? Chest 2001;119:327-8.
22. Calverley PM, Lee A, Towse L, van Noord JA, Witek TJ Jr, Kesten S. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax 2003;58:855-60.
23. O'Donnell DE, Fluge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, et al. Effects of tiotropium on lung hyperinflation, dyspnea, and exercise tolerance in COPD. Eur Respir J 2004;23:832-40.
24. Tashkin DP, Kesten S. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest 2003;123:1441-9.
25. Donohue JF, Menjoge SS, Kesten S. Tolerance to bronchodilating effects of salmeterol in COPD. Respir Med 2003;97:1014-20.
26. Donohue JF, van Noord JA, Bateman E, Langley S, Lee A, Witek TJ Jr, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002;122:47-55.
27. Witek TJ Jr, Mahler DA. Meaningful effect size and patterns of response of the transition dyspnea index. J Clin Epidemiol 2003;56:248-55.
28. Jones PW, Quirk FH, Baveystock CM. The St. George's respiratory questionnaire. Respir Med 1991;85(suppl B):25-31.
29. International abbreviated prescribing information for Spiriva HandiHaler. Boehringer Ingelheim, January 2004. www.spiriva.com/spiriva/index.jsp
30. O'Connor BJ, Towse LJ, Barnes PJ. Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma. Am J Respir Crit Care Med 1996;154:876-80.
31. Hansani A, Toms N, Agnew JE, Sarno M, Harrison AJ, Dilworth P. The effect of inhaled tiotropium bromide on lung mucociliary clearance in patients with COPD. Chest 2004;125:1726-34.
32. Turck D, Weber W, Sugmund R, Budde K, Neumayer H-H, Pritsche L, et al. Pharmacokinetics of intravenous, single-dose tiotropium in subjects with different degrees of renal impairment. J Clin Pharmacol 2004; 44:163-72.
33. Oostenbrink JB, Rutten-van Molken MP, Al MJ, van Noord JA, Vincken W. One year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive lung disease. Eur Respir J 2004;23:241-9.
34. Friedman M, Menjoge SS, Anton SF, Kesten S. Healthcare costs with tiotropium plus usual care versus usual care alone following one year of treatment in patients with chronic obstructive pulmonary disorder (COPD). Pharmacoeconomics 2004;22:741-9.
35. AmerisourceBergen Wholesaler Catalog, www.amerisource.com (accessed 2004 Nov 4).
36. Chodosh S, Flanders JS, Kesten S, Serby CW, Hochrainer D, Witek TJ Jr. Effective delivery of particles with the HandiHaler dry powder inhalation system over a range of chronic obstructive pulmonary disease severity. J Aerosol Med 2001;14:309-15.
37. Dahl R, Backer V, Ollgaard B, Gerken F, Kesten S. Assessment of patient performance of the HandiHaler compared with the metered dose inhaler four weeks after instruction. Respir Med 2003;97:1126-33.
38. National Institutes of Health. National Asthma Education and Prevention Program Expert Panel Report: guidelines for the diagnosis and management of asthma-update on selected topics 2002. Washington, DC: National Heart, Lung, and Blood Institute. NIH publication no. 02-5075 June 2002.